D

DefiniGEN

29 employees

Definigen provides human cells to the drug discovery sector for use in lead optimization and toxicity programs.

Basic info

Industry

biotechnology research

Sectors

Induced Pluripotent Stem Cells (iPSC)
Biotechnology
Inherited Metabolic Diseases (IMD)
Health Care
Hepatocytes
Toxicity testing
Pharmaceutical
Pancreatic Cells
Drug Discovery
Disease Modelling

Date founded

2012

Funding rounds raised

Total raised

$4.4M

from 8 investors over 8 rounds

D

DefiniGEN raised $4.4M on November 19, 2020

Investors: 24Haymarket

D

DefiniGEN raised $899K on November 1, 2018

Investors: 24Haymarket

D

DefiniGEN raised $2.2M on May 23, 2016

Investors: Cambridge Enterprise, Parkwalk Advisors, Cambridge Angels and 24Haymarket

D

DefiniGEN raised $3.9M on June 2, 2014

Investors: Cambridge Enterprise and 24Haymarket

FAQ